(c) 2024 PillSync.com

Dexmedetomidine Dailymed

  1. Human Prescription
  2. Central alpha-2 Adrenergic Agonist
  3. Accord Healthcare Inc.

Generic: dexmedetomidine is used for the treatment of Pain Psychomotor Agitation

Dexmedetomidine syringe - image

  1. FDA Adverse Reactions

Go PRO for all pill images

Recent Major Changes Section


Dosage and Administration, Preparation of Solution ( 2.4) 08/2022
Warnings and Precautions, Hyperthermia or Pyrexia ( 5.7) 08/2022

1 Indications And Usage



Dexmedetomidine injection is a alpha 2-adrenergic receptor agonist indicated for:
  • Sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting Administer dexmedetomidine injection by continuous infusion not to exceed 24 hours ( 1.1)
  • Sedation of non-intubated patients prior to and/or during surgical and other procedures ( 1.2)

1.1 Intensive Care Unit Sedation


Dexmedetomidine injection is indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting. Dexmedetomidine injection should be administered by continuous infusion not to exceed 24 hours.

Dexmedetomidine injection has been continuously infused in mechanically ventilated patients prior to extubation, during extubation, and post-extubation. It is not necessary to discontinue dexmedetomidine injection prior to extubation.

1.2 Procedural Sedation


Dexmedetomidine injection is indicated for sedation of non-intubated patients prior to and/or during surgical and other procedures.

2 Dosage And Administration


  • Individualize and titrate dexmedetomidine injection dosing to desired clinical effect. ( 2.1)
  • Administer dexmedetomidine injection using a controlled infusion device. ( 2.1)
  • Dilute the 200 mcg/2 mL (100 mcg/mL) vial contents in 0.9% sodium chloride solution to achieve required concentration (4 mcg/mL) prior to administration. ( 2.4)

For Adult Intensive Care Unit Sedation: Generally initiate at one mcg/kg over 10 minutes, followed by a maintenance

infusion of 0.2 to 0.7 mcg/kg/ hour.( 2.2)

For Adult Procedural Sedation: Generally initiate at one mcg/kg over 10 minutes, followed by a maintenance infusion initiated at 0.6 mcg/kg/ hour and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/ hour.( 2.2)

Alternative Doses:Recommended for patients over 65 years of age and awake fiberoptic intubation patients. ( 2.2)

2.1 Dosing Guidelines

  • Dexmedetomidine injection dosing should be individualized and titrated to desired clinical response.
  • Dexmedetomidine injection is not indicated for infusions lasting longer than 24 hours.
  • Dexmedetomidine injection should be administered using a controlled infusion device.

2.2 Dosage Information

Table 1: Dosage Information
INDICATION DOSAGE AND ADMINISTRATION
Initiation of Intensive Care Unit Sedation For adult patients: a loading infusion of one mcg/kg over 10 minutes. For adult patients being converted from alternate sedative therapy: a loading dose may not be required. For patients over 65 years of age: a dose reduction should be considered [ see Use in Specific Populations (8.5) ]. For adult patients with impaired hepatic-function: a dose reduction should be considered [ see Use in Specific Populations (8.6), Clinical Pharmacology (12.3) ].
Maintenance of Intensive Care Unit Sedation For adult patients: a maintenance infusion of 0.2 to 0.7 mcg/kg/ hour. The rate of the maintenance infusion should be adjusted to achieve the desired level of sedation. For patients over 65 years of age: a dose reduction should be considered [ see Use in Specific Populations (8.5) ] . For adult patients with impaired hepatic function: a dose reduction should be considered [ see Use in Specific Populations (8.6), Clinical Pharmacology (12.3) ].
Initiation of Procedural Sedation For adult patients: a loading infusion of one mcg/kg over 10  minutes. For less invasive procedures such as ophthalmic surgery, a loading infusion of 0.5 mcg/kg given over 10 minutes may be suitable. For awake fiberoptic intubation in adult patients: a loading infusion of one mcg/kg over 10 minutes. For patients over 65 years of age: a loading infusion of 0.5 mcg/kg over 10  minutes [ see Use in Specific Populations (8.5) ] . For adult patients with impaired hepatic function: a dose reduction should be considered [ see Use in Specific Populations (8.6), Clinical Pharmacology (12.3) ].
Maintenance of Procedural Sedation For adult patients: the maintenance infusion is generally initiated at 0.6 mcg/kg/ hour and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/ hour. The rate of the maintenance infusion should be adjusted to achieve the targeted level of sedation. For awake fiberoptic intubation in adult patients: a maintenance infusion of 0.7 mcg/kg/ hour is recommended until the endotracheal tube is secured. For patients over 65 years of age: a dose reduction should be considered [ see Use in Specific Populations (8.5) ] . For adult patients with impaired hepatic function: a dose reduction should be considered [ see Use in Specific Populations (8.6), Clinical Pharmacology (12.3) ].

2.3 Dosage Adjustment


Due to possible pharmacodynamic interactions, a reduction in dosage of dexmedetomidine injection or other concomitant anesthetics, sedatives, hypnotics or opioids may be required when co-administered [ see Drug Interactions (7.1) ].

Dosage reductions may need to be considered for adult patients with hepatic impairment, and geriatric patients [ see Warnings and Precautions (5.8) , Use in Specific Populations(8.6) , Clinical Pharmacology (12.3) ].

2.4 Preparation of Solution


Strict aseptic technique must always be maintained during handling of dexmedetomidine injection.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.Do not use if product is discolored or if precipitate matter is present.

Dexmedetomidine injection, 200 mcg/2 mL (100 mcg/mL)

Dexmedetomidine injection must be diluted with 0.9% sodium chloride injection to achieve required concentration (4 mcg/mL) prior to administration. Preparation of solutions is the same, whether for the loading dose or maintenance infusion.

To prepare the infusion, withdraw 2 mL of dexmedetomidine injection, and add to 48 mL of 0.9% sodium chloride injection to a total of 50 mL. Shake gently to mix well.

2.5 Administration with Other Fluids


Dexmedetomidine infusion should not be co-administered through the same intravenous catheter with blood or plasma because physical compatibility has not been established.

Dexmedetomidine injection has been shown to be incompatible when administered with the following drugs: amphotericin B, diazepam.

Dexmedetomidine injection has been shown to be compatible when administered with the following intravenous fluids:
  • 0.9% sodium chloride in water
  • 5% dextrose in water
  • 20% mannitol
  • Lactated Ringer's solution
  • 100 mg/mL magnesium sulfate solution
  • 0.3% potassium chloride solution

2.6 Compatibility with Natural Rubber


Compatibility studies have demonstrated the potential for absorption of dexmedetomidine injection to some types of natural rubber. Although dexmedetomidine injection is dosed to effect, it is advisable to use administration components made with synthetic or coated natural rubber gaskets.

3 Dosage Forms And Strengths


Dexmedetomidine injection, USP

Dexmedetomidine injection, USP is a clear and colorless solution, to be used after dilution. It is available as:
  • 200 mcg/2 mL (100 mcg/mL) single-dose vial.


Dexmedetomidine injection, USP, 200 mcg/2 mL (100 mcg/mL) in a single vial. To be used after dilution.

4 Contraindications


None


None. ( 4)

5 Warnings And Precautions


  • Monitoring: Continuously monitor patients while receiving dexmedetomidine injection. ( 5.1)
  • Bradycardia and Sinus Arrest: Have occurred in young healthy volunteers with high vagal tone or with different routes of administration, e.g., rapid intravenous or bolus administration. ( 5.2)
  • Hypotension and Bradycardia: May necessitate medical intervention. May be more pronounced in patients with hypovolemia, diabetes mellitus, or chronic hypertension, and in the elderly. Use with caution in patients with advanced heart block or severe ventricular dysfunction. ( 5.2)
  • Co-administration with Other Vasodilators or Negative Chronotropic Agents: Use with caution due to additive pharmacodynamic effects. ( 5.2)
  • Transient Hypertension: Observed primarily during the loading dose. Consider reduction in loading infusion rate. ( 5.3)
  • Arousability: Patients can become aroused/alert with stimulation; this alone should not be considered as lack of efficacy. ( 5.4)
  • Tolerance and Tachyphylaxis: Prolonged exposure to dexmedetomidine beyond 24 hours may be associated with tolerance and tachyphylaxis and a dose-related increase in adverse events ( 5.6)

5.1 Drug Administration


Dexmedetomidine injection should be administered only by persons skilled in the management of patients in the intensive care or operating room setting. Due to the known pharmacological effects of dexmedetomidine injection, patients should be continuously monitored while receiving dexmedetomidine injection.

5.2 Hypotension, Bradycardia, and Sinus Arrest


Clinically significant episodes of bradycardia and sinus arrest have been reported with dexmedetomidine injection administration in young, healthy adult volunteers with high vagal tone or with different routes of administration including rapid intravenous or bolus administration.

Reports of hypotension and bradycardia have been associated with dexmedetomidine infusion. Some of these cases have resulted in fatalities. If medical intervention is required, treatment may include decreasing or stopping the infusion of dexmedetomidine injection, increasing the rate of intravenous fluid administration, elevation of the lower extremities, and use of pressor agents. Because dexmedetomidine injection has the potential to augment bradycardia induced by vagal stimuli, clinicians should be prepared to intervene. The intravenous administration of anticholinergic agents (e.g., glycopyrrolate, atropine) should be considered to modify vagal tone. In clinical trials, glycopyrrolate or atropine were effective in the treatment of most episodes of dexmedetomidine-induced bradycardia. However, in some patients with significant cardiovascular dysfunction, more advanced resuscitative measures were required.

Caution should be exercised when administering dexmedetomidine injection to patients with advanced heart block and/or severe ventricular dysfunction. Because dexmedetomidine injection decreases sympathetic nervous system activity, hypotension and/or bradycardia may be expected to be more pronounced in patients with hypovolemia, diabetes mellitus, or chronic hypertension and in elderly patients.

In clinical trials where other vasodilators or negative chronotropic agents were co-administered with dexmedetomidine injection an additive pharmacodynamic effect was not observed. Nonetheless, caution should be used when such agents are administered concomitantly with dexmedetomidine injection.

5.3 Transient Hypertension


Transient hypertension has been observed primarily during the loading dose in association with the initial peripheral vasoconstrictive effects of dexmedetomidine injection. Treatment of the transient hypertension has generally not been necessary, although reduction of the loading infusion rate may be desirable.

5.4 Arousability


Some patients receiving dexmedetomidine injection have been observed to be arousable and alert when stimulated. This alone should not be considered as evidence of lack of efficacy in the absence of other clinical signs and symptoms.

5.5 Withdrawal


Intensive Care Unit Sedation

With administration up to 7 days, regardless of dose, 12 (5%) dexmedetomidine injection adult subjects experienced at least 1 event related to withdrawal within the first 24 hours after discontinuing study drug and 7 (3%) dexmedetomidine injection adult subjects experienced at least 1 event 24 to 48 hours after end of study drug. The most common events were nausea, vomiting, and agitation.

In adult subjects, tachycardia and hypertension requiring intervention in the 48 hours following study drug discontinuation occurred at frequencies of <5%. If tachycardia and/or hypertension occurs after discontinuation of dexmedetomidine injection supportive therapy is indicated.

Procedural Sedation

In adult subjects, withdrawal symptoms were not seen after discontinuation of short term infusions of dexmedetomidine injection (<6 hours).

5.6 Tolerance and Tachyphylaxis


Use of dexmedetomidine beyond 24 hours has been associated with tolerance and tachyphylaxis and a dose-related increase in adverse reactions [ see Adverse Reactions(6.1) ].

5.7 Hyperthermia or Pyrexia


Dexmedetomidine injection may induce hyperthermia or pyrexia, which may be resistant to traditional cooling methods, such as administration of cooled intravenous fluids and antipyretic medications. Discontinue dexmedetomidine injection if drug-related hyperthermia or pyrexia is suspected and monitor patients until body temperature normalizes.

5.8 Hepatic Impairment


Since dexmedetomidine injection clearance decreases with severity of hepatic impairment, dose reduction should be considered in patients with impaired hepatic function [ see Dosage and Administration ( 2.2, 2.3) ].

6 Adverse Reactions


The following clinically significant adverse reactions are described elsewhere in the labeling:

  • The most common adverse reactions (incidence > 2%) are hypotension, bradycardia, and dry mouth. (6.1)
  • Adverse reactions associated with infusions > 24 hours in duration include ARDS, respiratory failure, and agitation. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Accord Healthcare Inc. at 1-866-941-7875 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

6.1 Clinical Trials Experience


Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Most common treatment-emergent adverse reactions, occurring in greater than 2% of patients in both Intensive Care Unit and procedural sedation studies include hypotension, bradycardia and dry mouth.

Intensive Care Unit Sedation

Adverse reaction information is derived from the continuous infusion trials of dexmedetomidine injection for sedation in the Intensive Care Unit setting in which 1,007 adult patients received dexmedetomidine injection. The mean total dose was 7.4 mcg/kg (range: 0.8 to 84.1), mean dose per hour was 0.5 mcg/kg/hr (range: 0.1 to 6.0) and the mean duration of infusion of 15.9 hours (range: 0.2 to 157.2). The population was between 17 to 88 years of age, 43% ≥65 years of age, 77% male and 93% Caucasian. Treatment-emergent adverse reactions occurring at an incidence of >2% are provided in Table 2. The most frequent adverse reactions were hypotension, bradycardia and dry mouth [ see Warnings and Precautions (5.2) ].
Table 2: Adverse Reactions with an Incidence >2%—Adult Intensive Care Unit Sedation Population <24 hours 26 subjects in the all dexmedetomidine injection group and 10 subjects in the randomized dexmedetomidine injection group had exposure for greater than 24 hours.
Adverse Event All Dexmedetomidine injection (N = 1007) (%) Randomized Dexmedetomidine injection (N = 798) (%) Placebo (N = 400) (%) Propofol (N = 188) (%)
Hypotension
25%
24%
12%
13%
Hypertension
12%
13%
19%
4%
Nausea
9%
9%
9%
11%
Bradycardia
5%
5%
3%
0
Atrial Fibrillation
4%
5%
3%
7%
Pyrexia
4%
4%
4%
4%
Dry Mouth
4%
3%
1%
1%
Vomiting
3%
3%
5%
3%
Hypovolemia
3%
3%
2%
5%
Atelectasis
3%
3%
3%
6%
Pleural Effusion
2%
2%
1%
6%
Agitation
2%
2%
3%
1%
Tachycardia
2%
2%
4%
1%
Anemia
2%
2%
2%
2%
Hyperthermia
2%
2%
3%
0
Chills
2%
2%
3%
2%
Hyperglycemia
2%
2%
2%
3%
Hypoxia
2%
2%
2%
3%
Post-procedural Hemorrhage
2%
2%
3%
4%
Pulmonary Edema
1%
1%
1%
3%
Hypocalcemia
1%
1%
0
2%
Acidosis
1%
1%
1%
2%
Urine Output Decreased
1%
1%
0
2%
Sinus Tachycardia
1%
1%
1%
2%
Ventricular Tachycardia
<1%
1%
1%
5%
Wheezing
<1%
1%
0
2%
Edema Peripheral
<1%
0
1%
2%

Adverse reaction information was also derived from the placebo-controlled, continuous infusion trials of dexmedetomidine injection for sedation in the surgical intensive care unit setting in which 387 adult patients received dexmedetomidine injection for less than 24 hours. The most frequently observed treatment-emergent adverse events included hypotension, hypertension, nausea, bradycardia, fever, vomiting, hypoxia, tachycardia and anemia (see Table 3).
Table 3: Treatment-Emergent Adverse Events Occurring in >1% Of All Dexmedetomidine-Treated Adult Patients in the Randomized Placebo-Controlled Continuous Infusion <24 Hours ICU Sedation Studies
Adverse Event Randomized Dexmedetomidine (N = 387)
Placebo

(N = 379)
Hypotension
28%
13%
Hypertension
16%
18%
Nausea
11%
9%
Bradycardia
7%
3%
Fever
5%
4%
Vomiting
4%
6%
Atrial Fibrillation
4%
3%
Hypoxia
4%
4%
Tachycardia
3%
5%
Hemorrhage
3%
4%
Anemia
3%
2%
Dry Mouth
3%
1%
Rigors
2%
3%
Agitation
2%
3%
Hyperpyrexia
2%
3%
Pain
2%
2%
Hyperglycemia
2%
2%
Acidosis
2%
2%
Pleural Effusion
2%
1%
Oliguria
2%
<1%
Thirst
2%
<1%

In a controlled clinical trial, dexmedetomidine injection was compared to midazolam for ICU sedation exceeding 24 hours duration in adult patients. Key treatment emergent adverse events occurring in dexmedetomidine or midazolam treated patients in the randomized active comparator continuous infusion long-term intensive care unit sedation study are provided in Table 4. The number (%) of subjects who had a dose-related increase in treatment-emergent adverse events by maintenance adjusted dose rate range in the dexmedetomidine injection group is provided in Table 5.
Table 4: Key Treatment-Emergent Adverse Events Occurring in Dexmedetomidine- or Midazolam-Treated Adult Patients in the Randomized Active Comparator Continuous Infusion Long-Term Intensive Care Unit Sedation Study
Adverse Event Dexmedetomidine (N = 244)
Midazolam

(N = 122)
Hypotension Hypotension was defined in absolute terms as Systolic blood pressure of <80 mmHg or Diastolic blood pressure of <50 mmHg or in relative terms as ≤30% lower than pre-study drug infusion value. 56%
56%
Hypotension Requiring Intervention 28%
27%
Bradycardia Bradycardia was defined in absolute terms as <40 bpm or in relative terms as ≤30% lower than pre-study drug infusion value. 42%
19%
Bradycardia Requiring Intervention 5%
1%
Systolic Hypertension Hypertension was defined in absolute terms as Systolic blood pressure >180 mmHg or Diastolic blood pressure of >100 mmHg or in relative terms as ≥30% higher than pre-study drug infusion value. 28%
42%
Tachycardia Tachycardia was defined in absolute terms as >120 bpm or in relative terms as ≥30% greater than pre-study drug infusion value. 25%
44%
Tachycardia Requiring Intervention 10%
10%
Diastolic Hypertension 12%
15%
Hypertension 11%
15%
Hypertension Requiring Intervention Includes any type of hypertension. 19%
30%
Hypokalemia 9%
13%
Pyrexia 7%
2%
Agitation 7%
6%
Hyperglycemia 7%
2%
Constipation 6%
6%
Hypoglycemia 5%
6%
Respiratory Failure 5%
3%
Renal Failure Acute 2%
1%
Acute Respiratory Distress Syndrome 2%
1%
Generalized Edema 2%
6%
Hypomagnesemia 1%
7%

The following adverse events occurred between 2 and 5% for dexmedetomidine injection and Midazolam, respectively: renal failure acute (2.5%, 0.8%), acute respiratory distress syndrome (2.5%, 0.8%), and respiratory failure (4.5%, 3.3%).
Table 5. Number (%) of Adult Subjects Who Had a Dose-Related Increase in Treatment Emergent Adverse Events by Maintenance Adjusted Dose Rate Range in the dexmedetomidine injection Group
Dexmedetomidine injection mcg/kg/hr
Adverse Event
≤0.7 Average maintenance dose over the entire study drug administration

(N = 95)

>0.7 to ≤1.1

(N = 78)
>1.1 (N = 71)
Constipation
6%
5%
 14%
Agitation
5%
8%
 14%
Anxiety
5%
5%
 9%
Edema Peripheral
3%
5%
 7%
Atrial Fibrillation
2%
4%
 9%
Respiratory Failure
2%
6%
 10%
Acute Respiratory Distress Syndrome
1%
3%
 9%

Procedural Sedation

Adverse reaction information is derived from the two trials for procedural sedation [see Clinical Studies (14.2)] in which 318 adult patients received dexmedetomidine. The mean total dose was 1.6 mcg/kg (range: 0.5 to 6.7), mean dose per hour was 1.3 mcg/kg/hr (range: 0.3 to 6.1) and the mean duration of infusion of 1.5 hours (range: 0.1 to 6.2). The population was between 18 to 93 years of age, ASA I-IV, 30% ≥ 65 years of age, 52% male and 61% Caucasian.

Treatment-emergent adverse reactions occurring at an incidence of >2% are provided in Table 6. The most frequent adverse reactions were hypotension, bradycardia, and dry mouth [ see Warnings and Precautions (5.2) ]. Pre- specified criteria for the vital signs to be reported as adverse reactions are footnoted below the table. The decrease in respiratory rate and hypoxia was similar between dexmedetomidine and comparator groups in both studies.
Table 6: Adverse Reactions with an Incidence > 2%—Procedural Sedation Population

Adverse Event

Dexmedetomidine (N = 318) (%)

Placebo (N = 113) (%)

Hypotension Hypotension was defined in absolute and relative terms as Systolic blood pressure of < 80 mmHg or ≤ 30% lower than pre-study drug infusion value, or Diastolic blood pressure of < 50 mmHg.

54%
30%

Respiratory Depression Respiratory depression was defined in absolute and relative terms as respiratory rate (RR) < 8 beats per minute or > 25% decrease from baseline.

37%
32%

Bradycardia Bradycardia was defined in absolute and relative terms as < 40 beats per minute or ≤ 30% lower than pre-study drug infusion value.

14%
4%

Hypertension Hypertension was defined in absolute and relative terms as Systolic blood pressure > 180 mmHg or ≥ 30% higher than pre-study drug infusion value or Diastolic blood pressure of > 100 mmHg.

13%
24%

Tachycardia Tachycardia was defined in absolute and relative terms as > 120 beats per minute or ≥ 30% greater than pre-study drug infusion value.

5%
17%

Nausea

3%
2%

Dry Mouth

3%
1%

Hypoxia Hypoxia was defined in absolute and relative terms as SpO 2 < 90% or 10% decrease from baseline.

2%
3%

Bradypnea

2%
4%

6.2 Postmarketing Experience


The following adverse reactions have been identified during post approval use of dexmedetomidine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Hypotension and bradycardia were the most common adverse reactions associated with the use of dexmedetomidine during post approval use of the drug.
Table 7: Adverse Reactions Experienced During Post-Approval Use of Dexmedetomidine
System Organ Class Preferred Term

Blood and Lymphatic System Disorders  
Anemia

Cardiac Disorders 
Arrhythmia, atrial fibrillation, atrioventricular block, bradycardia, cardiac arrest, cardiac disorder, extrasystoles, myocardial infarction, supraventricular tachycardia, tachycardia, ventricular arrhythmia, ventricular tachycardia

Eye Disorders
Photopsia, visual impairment

Gastrointestinal Disorders
Abdominal pain, diarrhea, nausea, vomiting

General Disorders and Administration Site Conditions
Chills, hyperpyrexia, pain, pyrexia, thirst

Hepatobiliary Disorders
Hepatic function abnormal, hyperbilirubinemia

Investigations
Alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood urea increased, electrocardiogram T wave inversion, gammaglutamyl transferase increased, electrocardiogram QT prolonged

Metabolism and Nutrition Disorders
Acidosis, hyperkalemia, hypoglycemia, hypovolemia, hypernatremia

Nervous System Disorders

Convulsion, dizziness, headache, neuralgia, neuritis, speech disorder

Psychiatric Disorders
Agitation, confusional state, delirium, hallucination, illusion

Renal and Urinary Disorders
Oliguria, polyuria

Respiratory, Thoracic and Mediastinal Disorders

Apnea, bronchospasm, dyspnea, hypercapnia, hypoventilation, hypoxia, pulmonary congestion, respiratory acidosis

Skin and Subcutaneous Tissue Disorders
Hyperhidrosis, pruritus, rash, urticaria

Surgical and Medical Procedures
Light anesthesia

Vascular Disorders
Blood pressure fluctuation, hemorrhage, hypertension, hypotension

7 Drug Interactions



Anesthetics, Sedatives, Hypnotics, Opioids: Enhancement of pharmacodynamic effects. Reduction in dosage of dexmedetomidine injection or the concomitant medication may be required. (7.1)

7.1 Anesthetics, Sedatives, Hypnotics, Opioids


Co-administration of dexmedetomidine with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam. No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil and midazolam have been demonstrated. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine or the concomitant anesthetic, sedative, hypnotic or opioid may be required.

7.2 Neuromuscular Blockers


In one study of 10 healthy adult volunteers, administration of dexmedetomidine for 45 minutes at a plasma concentration of one ng/mL resulted in no clinically meaningful increases in the magnitude of neuromuscular blockade associated with rocuronium administration.

8 Use In Specific Populations



  • Geriatric Patients: Dose reduction should be considered (2.2, 2.3, 5.2, 8.5)

  • Hepatic Impairment: Dose reduction should be considered ( 2.2, 2.3, 5.8, 8.6)

8.1 Pregnancy


Risk Summary

Available data from published randomized controlled trials and case reports over several decades of use with intravenously administered dexmedetomidine during pregnancy have not identified a drug-associated risk of major birth defects and miscarriage; however, the reported exposures occurred after the first trimester. Most of the available data are based on studies with exposures that occurred at the time of caesarean section delivery, and these studies have not identified an adverse effect on maternal outcomes or infant Apgar scores. Available data indicate that dexmedetomidine crosses the placenta.

In animal reproduction studies, fetal toxicity that lower fetal viability and reduced live fetuses occurred with subcutaneous administration of dexmedetomidine to pregnant rats during organogenesis at doses 1.8 times the maximum recommended human dose (MRHD) of 17.8 mcg/kg/day.

Developmental toxicity (low pup weights and adult offspring weights, decreased F1 grip strength, increased early implantation loss and decreased viability of second-generation offspring) occurred when pregnant rats were subcutaneously administered dexmedetomidine at doses less than the clinical dose from late pregnancy through lactation and weaning (see Data).

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Data

Animal Data

Increased post-implantation losses and reduced live fetuses in the presence of maternal toxicity (i.e. decreased body weight) were noted in a rat embryo-fetal development study in which pregnant dams were administered subcutaneous doses of dexmedetomidine 200 mcg/kg/day (equivalent to 1.8 times the intravenous MRHD of 17.8 mcg/kg/day based on body surface area [BSA]) during the period of organogenesis (Gestation Day [GD] 6 to 15). No malformations were reported.

No malformations or embryo-fetal toxicity were noted in a rabbit embryo-fetal development study in which pregnant does were administered dexmedetomidine intravenously at doses of up to 96 mcg/kg/day (approximately half the human exposure at the MRHD based on AUC) during the period of organogenesis (GD 6 to 18).

Reduced pup and adult offspring birth weights, and grip strength were reported in a rat developmental toxicology study in which pregnant females were administered dexmedetomidine subcutaneously at doses of 8 mcg/kg/day (0.07 times the MRHD based on BSA) during late pregnancy through lactation and weaning (GD 16 to postnatal day [PND] 25). Decreased viability of second generation offspring and an increase in early implantation loss along with delayed motor development occurred in the 32 mcg/kg/day group (equivalent to less than the clinical dose based on BSA) when first generation offspring were allowed to mate. This study limited dosing to hard palate closure (GD 15 to 18) through weaning instead of dosing from implantation (GD 6 to 7) to weaning (PND 21).

In a study in the pregnant rat, placental transfer of dexmedetomidine was observed when radiolabeled dexmedetomidine was administered subcutaneously.

8.2 Lactation


Risk Summary

Available published literature reports the presence of dexmedetomidine in human milk following intravenous administration (see Data). There is no information regarding the effects of dexmedetomidine on the breastfed infant or the effects on milk production. Advise women to monitor the breastfed infant for irritability. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for dexmedetomidine and any potential adverse effects on the breastfed infant from dexmedetomidine or from the underlying condition.

Data

In two published clinical studies, a total of 14 women were given intravenous dexmedetomidine 6 mcg/kg/hour for 10 minutes after delivery followed by continuous infusion of 0.2–0.7 mcg/kg/hour. Breast milk and maternal blood samples were collected at 0, 6, 12, and 24 hours after discontinuation of dexmedetomidine. Plasma and milk dexmedetomidine concentrations were detectable up to 6 hours in most subjects, up to 12 hours in one subject and undetectable in all at 24 hours. The milk-to-plasma ratio from single paired maternal milk and plasma concentrations at each time point ranged from 0.53 to 0.95. The relative infant dose was estimated to range from 0.02 to 0.098%.

8.4 Pediatric Use


Safety and efficacy have not been established for Procedural or ICU Sedation in pediatric patients. One assessor-blinded trial in pediatric patients and two open label studies in neonates were conducted to assess efficacy for ICU sedation. These studies did not meet their primary efficacy endpoints and the safety data submitted were insufficient to fully characterize the safety profile of dexmedetomidine for this patient population. The use of dexmedetomidine for procedural sedation in pediatric patients has not been evaluated.

8.5 Geriatric Use


Intensive Care Unit Sedation

A total of 729 patients in the clinical studies were 65 years of age and over. A total of 200 patients were 75 years of age and over. In patients greater than 65 years of age, a higher incidence of bradycardia and hypotension was observed following administration of dexmedetomidine injection [ see Warnings and Precautions (5.2) ]. Therefore a dose reduction may be considered in patients over 65 years of age [ see Dosage and Administration ( 2.2, 2.3), Clinical Pharmacology (12.3) ].

Procedural Sedation

A total of 131 patients in the clinical studies were 65 years of age and over. A total of 47 patients were 75 years of age and over. Hypotension occurred in a higher incidence in dexmedetomidine -treated patients 65 years or older (72%) and 75 years or older (74%) as compared to patients <65 years (47%). A reduced loading dose of 0.5 mcg/kg given over 10 minutes is recommended and a reduction in the maintenance infusion should be considered for patients greater than 65 years of age.

8.6 Hepatic Impairment


Since dexmedetomidine clearance decreases with increasing severity of hepatic impairment, dose reduction should be considered in patients with impaired hepatic function [ see  Dosage and Administration ( 2.2, 2.3) , Clinical Pharmacology (12.3) ].

9 Drug Abuse And Dependence


9.1 Controlled Substance


Dexmedetomidine hydrochloride is not a controlled substance.

9.3 Dependence


The dependence potential of dexmedetomidine has not been studied in humans. However, since studies in rodents and primates have demonstrated that dexmedetomidine exhibits pharmacologic actions similar to those of clonidine, it is possible that dexmedetomidine may produce a clonidine-like withdrawal syndrome upon abrupt discontinuation [ see Warnings and Precautions (5.5) ].

10 Overdosage


The tolerability of dexmedetomidine injection was studied in one study in which healthy adult subjects were administered doses at and above the recommended dose of 0.2 to 0.7 mcg/kg/hr. The maximum blood concentration achieved in this study was approximately 13 times the upper boundary of the therapeutic range. The most notable effects observed in two subjects who achieved the highest doses were first degree atrioventricular block and second degree heart block. No hemodynamic compromise was noted with the atrioventricular block and the heart block resolved spontaneously within one minute.

Five adult patients received an overdose of dexmedetomidine injection in the intensive care unit sedation studies. Two of these patients had no symptoms reported; one patient received a 2 mcg/kg loading dose over 10 minutes (twice the recommended loading dose) and one patient received a maintenance infusion of 0.8 mcg/kg/hr. Two other patients who received a 2 mcg/kg loading dose over 10 minutes, experienced bradycardia and/or hypotension. One patient who received a loading bolus dose of undiluted dexmedetomidine injection (19.4 mcg/kg), had cardiac arrest from which he was successfully resuscitated.

11 Description


Dexmedetomidine injection, USP (100 mcg/mL) is a sterile, nonpyrogenic solution suitable for intravenous infusion following dilution. Dexmedetomidine injection, USP contains dexmedetomidine hydrochloride as the active pharmaceutical ingredient. Dexmedetomidine hydrochloride is a central alpha 2-adrenergic agonist. Dexmedetomidine hydrochloride is the S-enantiomer of medetomidine. Dexmedetomidine hydrochloride chemical name is 1H-Imidazole, 4-[1-(2,3dimethylphenyl)ethyl]-, monohydrochloride, (S). Dexmedetomidine hydrochloride has a molecular weight of 236.7 and the empirical formula is C 13H 16N 2 • HCl and the structural formula is:



Dexmedetomidine hydrochloride, USP is a white or almost white powder that is freely soluble in water and has a pKa of 7.1. Its partition coefficient in-octanol: water at pH 7.4 is 2.89.

Dexmedetomidine injection, USP is intended to be used after dilution. It is supplied as a clear, colorless, isotonic solution with a pH ofbetween 4.5 to 7.0. Each mL contains 118 mcg of dexmedetomidine hydrochloride (equivalent to 100 mcg or 0.1 mg of dexmedetomidine) and 9 mg of sodium chloride in water for injection and is to be used after dilution. The solution is preservative-free and contains no additives or chemical stabilizers.

12 Clinical Pharmacology


12.1 Mechanism of Action


Dexmedetomidine is a relatively selective centrally acting alpha 2-adrenergic agonist with sedative properties. Alpha 2 selectivity is observed in animals following slow intravenous infusion of low and medium doses (10 - 300 mcg/kg). Both alpha 1 and alpha 2 activity is observed following slow intravenous infusion of high doses (≥ 1,000 mcg/kg) or with rapid intravenous administration.

12.2 Pharmacodynamics


In a study in healthy volunteers (N=10), respiratory rate and oxygen saturation remained within normal limits and there was no evidence of respiratory depression when dexmedetomidine injection was administered by intravenous infusion at doses within the recommended dose range (0.2 - 0.7 mcg/kg/hr).

12.3 Pharmacokinetics


Following intravenous administration, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2) of approximately 6 minutes; a terminal elimination half-life (t 1/2) of approximately 2 hours; and steady-state volume of distribution (V ss) of approximately 118 liters. Clearance is estimated to be approximately 39 L/h. The mean body weight associated with this clearance estimate was 72 kg.

Dexmedetomidine exhibits linear pharmacokinetics in the dosage range of 0.2 to 0.7 mcg/kg/hr when administered by intravenous infusion for up to 24 hours. Table 8 shows the main pharmacokinetic parameters when dexmedetomidine injection was infused (after appropriate loading doses) at maintenance infusion rates of 0.17 mcg/kg/hr (target plasma concentration of 0.3 ng/mL) for 12 and 24 hours, 0.33 mcg/kg/hr (target plasma concentration of 0.6 ng/mL) for 24 hours, and 0.70 mcg/kg/hr (target plasma concentration of 1.25 ng/mL) for 24 hours.
Table 8: Mean ± SD Pharmacokinetic Parameters
Abbreviations: t 1/2 = half-life, CL = clearance, V ss = steady-state volume of distribution.

Parameter

Loading Infusion (min)/Total Infusion Duration (hrs)

10 min/12 hrs

10 min/24 hrs

10 min/24 hrs

35 min/24 hrs

Dexmedetomidine Target Plasma Concentration (ng/mL) and Dose (mcg/kg/hr)

0.3/0.17

0.3/0.17

0.6/0.33

1.25/0.70

t 1/2 Presented as harmonic mean and pseudo standard deviation. , hour

1.78 ± 0.30
2.22 ± 0.59
2.23 ± 0.21
2.50 ± 0.61

CL, liter/hour

46.3 ± 8.3
43.1 ± 6.5
35.3 ± 6.8
36.5 ± 7.5

V ss, liter

88.7 ± 22.9
102.4 ± 20.3
93.6 ± 17.0
99.6 ± 17.8

Avg C ss Mean C ss = Average steady-state concentration of dexmedetomidine. The mean C ss was calculated based on post-dose sampling from 2.5 to 9 hours samples for 12 hour infusion and post-dose sampling from 2.5 to 18 hours for 24 hour infusions. The loading doses for each of the above indicated groups were 0.5, 0.5, 1 and 2.2 mcg/kg, respectively. , ng/mL

0.27 ± 0.05
0.27 ± 0.05
0.67 ± 0.10
1.37 ± 0.20

Dexmedetomidine pharmacokinetic parameters after dexmedetomidine injection maintenance doses of 0.2 to 1.4 mcg/kg/hr for >24 hours were similar to the pharmacokinetic (PK) parameters after dexmedetomidine injection maintenance dosing for <24 hours in other studies. The values for clearance (CL), volume of distribution (V), and t 1/2 were 39.4 L/hr, 152 L, and 2.67 hours, respectively. 

Distribution

The steady-state volume of distribution (V ss) of dexmedetomidine was approximately 118 liters. Dexmedetomidine protein binding was assessed in the plasma of normal healthy male and female subjects. The average protein binding was 94% and was constant across the different plasma concentrations tested. Protein binding was similar in males and females. The fraction of dexmedetomidine that was bound to plasma proteins was significantly decreased in subjects with hepatic impairment compared to healthy subjects.

The potential for protein binding displacement of dexmedetomidine by fentanyl, ketorolac, theophylline, digoxin and lidocaine was explored in vitro , and negligible changes in the plasma protein binding of dexmedetomidine were observed. The potential for protein binding displacement of phenytoin, warfarin, ibuprofen, propranolol, theophylline and digoxin by dexmedetomidine was explored in vitro and none of these compounds appeared to be significantly displaced by dexmedetomidine.

Elimination

Metabolism

Dexmedetomidine undergoes almost complete biotransformation with very little unchanged dexmedetomidine excreted in urine and feces. Biotransformation involves both direct glucuronidation as well as cytochrome P450 mediated metabolism. The major metabolic pathways of dexmedetomidine are: direct N-glucuronidation to inactive metabolites; aliphatic hydroxylation (mediated primarily by CYP2A6 with a minor role of CYP1A2, CYP2E1, CYP2D6 and CYP2C19) of dexmedetomidine to generate 3-hydroxy-dexmedetomidine, the glucuronide of 3-hydroxy-dexmedetomidine, and 3-carboxydexmedetomidine; and N-methylation of dexmedetomidine to generate 3-hydroxy N-methyl-dexmedetomidine, 3-carboxy N-methyl-dexmedetomidine, and dexmedetomidine-N-methyl O-glucuronide.

Excretion

The terminal elimination half-life (t 1/2) of dexmedetomidine is approximately 2 hours and clearance is estimated to be approximately 39 L/h. A mass balance study demonstrated that after nine days an average of 95% of the radioactivity, following intravenous administration of radiolabeled dexmedetomidine, was recovered in the urine and 4% in the feces. No unchanged dexmedetomidine was detected in the urine. Approximately 85% of the radioactivity recovered in the urine was excreted within 24 hours after the infusion. Fractionation of the radioactivity excreted in urine demonstrated that products of N-glucuronidation accounted for approximately 34% of the cumulative urinary excretion. In addition, aliphatic hydroxylation of parent drug to form 3-hydroxy- dexmedetomidine, the glucuronide of 3-hydroxy-dexmedetomidine, and 3-carboxylic acid-dexmedetomidine together represented approximately 14% of the dose in urine. N-methylation of dexmedetomidine to form 3 hydroxy N-methyl dexmedetomidine, 3-carboxy N-methyl dexmedetomidine, and N methyl O-glucuronide dexmedetomidine accounted for approximately 18% of the dose in urine. The N-Methyl metabolite itself was a minor circulating component and was undetected in urine. Approximately 28% of the urinary metabolites have not been identified.

Specific Populations

Male and Female patients

There was no observed difference in dexmedetomidine pharmacokinetics due to sex.

Geriatric Patients

The pharmacokinetic profile of dexmedetomidine was not altered by age. There were no differences in the pharmacokinetics of dexmedetomidine in young (18 - 40 years), middle age (41 - 65 years), and elderly (>65 years) subjects.

Patients with Hepatic Impairment

In subjects with varying degrees of hepatic impairment (Child-Pugh Class A, B, or C), clearance values for dexmedetomidine were lower than in healthy subjects. The mean clearance values for patients with mild, moderate, and severe hepatic impairment were 74%, 64% and 53% of those observed in the normal healthy subjects, respectively. Mean clearances for free drug were 59%, 51% and 32% of those observed in the normal healthy subjects, respectively.

Although dexmedetomidine is dosed to effect, it may be necessary to consider dose reduction in subjects with hepatic impairment [ see Dosage and Administration (2.2), Warnings and Precautions (5.8) ].

Patients with Renal Impairment

Dexmedetomidine pharmacokinetics (Cmax, Tmax, AUC, t 1/2, CL, and V SS) were not significantly different in patients with severe renal impairment (creatinine clearance: <30 mL/min) compared to healthy subjects.

Drug Interaction Studies

In vitro studies: In vitro studies in human liver microsomes demonstrated no evidence of cytochrome P450 mediated drug interactions that are likely to be of clinical relevance.

13 Nonclinical Toxicology


13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility


Carcinogenesis

Animal carcinogenicity studies have not been performed with dexmedetomidine.

Mutagenesis

Dexmedetomidine was not mutagenic in vitro, in either the bacterial reverse mutation assay (E. coli and Salmonella typhimurium) or the mammalian cell forward mutation assay (mouse lymphoma). Dexmedetomidine was clastogenic in the in vitro human lymphocyte chromosome aberration test with, but not without, rat S9 metabolic activation. In contrast, dexmedetomidine was not clastogenic in the in vitro human lymphocyte chromosome aberration test with or without human S9 metabolic activation. Although dexmedetomidine was clastogenic in an in vivo mouse micronucleus test in NMRI mice, there was no evidence of clastogenicity in CD-1 mice.

Impairment of Fertility

Fertility in male or female rats was not affected after daily subcutaneous injections of dexmedetomidine at doses up to 54 mcg/kg (less than the maximum recommended human intravenous dose on a mcg/m 2 basis) administered from 10 weeks prior to mating in males, and 3 weeks prior to mating and during mating in females.

13.2 Animal Toxicology and/or Pharmacology


There were no differences in the adrenocorticotropic hormone (ACTH)-stimulated cortisol response in dogs following a single dose of dexmedetomidine compared to saline control. However, after continuous subcutaneous infusions of dexmedetomidine at 3 mcg/kg/hr and 10 mcg/kg/hr for one week in dogs (exposures estimated to be within the clinical range), the ACTH-stimulated cortisol response was diminished by approximately 27% and 40%, respectively, compared to saline-treated control animals indicating a dose- dependent adrenal suppression.

14 Clinical Studies


The safety and efficacy of dexmedetomidine has been evaluated in four randomized, double-blind, placebo-controlled multicenter clinical trials in 1,185 adult patients.

14.1 Intensive Care Unit Sedation


Two randomized, double-blind, parallel-group, placebo-controlled multicenter clinical trials included 754 adult patients being treated in a surgical intensive care unit. All patients were initially intubated and received mechanical ventilation. These trials evaluated the sedative properties of dexmedetomidine injection by comparing the amount of rescue medication (midazolam in one trial and propofol in the second) required to achieve a specified level of sedation (using the standardized Ramsay Sedation Scale) between dexmedetomidine injection and placebo from onset of treatment to extubation or to a total treatment duration of 24 hours. The Ramsay Level of Sedation Scale is displayed in Table 9.
Table 9: Ramsay Level of Sedation Scale
Clinical Score Level of Sedation Achieved

6
 Asleep, no response

5
 Asleep, sluggish response to light glabellar tap or loud auditory stimulus

4
 Asleep, but with brisk response to light glabellar tap or loud auditory stimulus

3
 Patient responds to commands

2
 Patient cooperative, oriented, and tranquil

1
 Patient anxious, agitated, or restless

In the first study, 175 adult patients were randomized to receive placebo and 178 to receive dexmedetomidine injection by intravenous infusion at a dose of 0.4 mcg/kg/hr (with allowed adjustment between 0.2 and 0.7 mcg/kg/hr) following an initial loading infusion of one mcg/kg intravenous over 10 minutes. The study drug infusion rate was adjusted to maintain a Ramsay sedation score of ≥3. Patients were allowed to receive “rescue†midazolam as needed to augment the study drug infusion. In addition, morphine sulfate was administered for pain as needed. The primary outcome measure for this study was the total amount of rescue medication (midazolam) needed to maintain sedation as specified while intubated. Patients randomized to placebo received significantly more midazolam than patients randomized to dexmedetomidine injection (see Table 10).

A second prospective primary analysis assessed the sedative effects of dexmedetomidine injection by comparing the percentage of patients who achieved a Ramsay sedation score of ≥3 during intubation without the use of additional rescue medication. A significantly greater percentage of patients in the dexmedetomidine injection group maintained a Ramsay sedation score of ≥3 without receiving any midazolam rescue compared to the placebo group (see Table 10).
Table 10: Midazolam Use as Rescue Medication During Intubation (ITT) Study One
ITT (intent-to-treat) population includes all randomized patients.
Placebo (N = 175)
Dexmedetomidine injection (N = 178)
p-value
Mean Total Dose (mg) of Midazolam Standard deviation 19 mg 53 mg 5 mg 19 mg 0.0011 ANOVA model with treatment center.
Categorized Midazolam Use
0 mg
43 (25%)
 108 (61%)
<0.001 Chi-square
0–4 mg
34 (19%)
 36 (20%)
>4 mg
98 (56%)
 34 (19%)

A prospective secondary analysis assessed the dose of morphine sulfate administered to patients in the dexmedetomidine injection and placebo groups. On average, dexmedetomidine injection-treated patients received less morphine sulfate for pain than placebo-treated patients (0.47 versus 0.83 mg/h). In addition, 44% (79 of 178 patients) of dexmedetomidine injection patients received no morphine sulfate for pain versus 19% (33 of 175 patients) in the placebo group.

In a second study, 198 adult patients were randomized to receive placebo and 203 to receive dexmedetomidine injection by intravenous infusion at a dose of 0.4 mcg/kg/hr (with allowed adjustment between 0.2 and 0.7 mcg/kg/hr) following an initial loading infusion of one mcg/kg intravenous over 10 minutes. The study drug infusion was adjusted to maintain a Ramsay sedation score of ≥3. Patients were allowed to receive “rescue†propofol as needed to augment the study drug infusion. In addition, morphine sulfate was administered as needed for pain. The primary outcome measure for this study was the total amount of rescue medication (propofol) needed to maintain sedation as specified while intubated.

Patients randomized to placebo received significantly more propofol than patients randomized to dexmedetomidine injection (see Table 11).

A significantly greater percentage of patients in the dexmedetomidine injection group compared to the placebo group maintained a Ramsay sedation score of ≥3 without receiving any propofol rescue (see Table 11).
Table 11: Propofol Use as Rescue Medication During Intubation (ITT) Study Two
Placebo (N = 198)
Dexmedetomidine injection (N = 203)

p-value

Mean Total Dose (mg) of Propofol

Standard deviation
 513 mg 782 mg
72 mg 249 mg

<0.0001 ANOVA model with treatment center.
Categorized Propofol Use

0 mg
47 (24%)
122 (60%)
<0.001 Chi-square

0–50 mg
30 (15%)
43 (21%)

>50 mg
121 (61%)
38 (19%)

A prospective secondary analysis assessed the dose of morphine sulfate administered to patients in the dexmedetomidine injection and placebo groups. On average, dexmedetomidine injection-treated patients received less morphine sulfate for pain than placebo-treated patients (0.43 versus 0.89 mg/h). In addition, 41% (83 of 203 patients) of dexmedetomidine injection patients received no morphine sulfate for pain versus 15% (30 of 198 patients) in the placebo group.

In a controlled clinical trial, dexmedetomidine injection was compared to midazolam for ICU sedation exceeding 24 hours duration. dexmedetomidine injection was not shown to be superior to midazolam for the primary efficacy endpoint, the percent of time patients were adequately sedated (81% versus 81%). In addition, administration of dexmedetomidine injection for longer than 24 hours was associated with tolerance, tachyphylaxis, and a dose-related increase in adverse events [ see Adverse Reactions (6.1)].

14.2 Procedural Sedation


The safety and efficacy of dexmedetomidine for sedation of non-intubated patients prior to and/or during surgical and other procedures was evaluated in two randomized, double-blind, placebo-controlled multicenter clinical trials. Study 1 evaluated the sedative properties of dexmedetomidine in patients having a variety of elective surgeries/procedures performed under monitored anesthesia care. Study 2 evaluated dexmedetomidine in patients undergoing awake fiberoptic intubation prior to a surgical or diagnostic procedure.

In Study 1, the sedative properties of dexmedetomidine were evaluated by comparing the percent of patients not requiring rescue midazolam to achieve a specified level of sedation using the standardized Observer’s Assessment of Alertness/Sedation Scale ( see Table 12).
Table 12: Observer’s Assessment of Alertness/Sedation
Assessment Categories
Responsiveness Speech Facial Expression Eyes Composite Score

Responds readily to name spoken in normal tone
Normal
Normal
Clear, no ptosis
5 (alert)

Lethargic response to name spoken in normal tone
Mild slowing or thickening
Mild relaxation
Glazed or mild ptosis (less than half the eye)
4

Responds only after name is called loudly and/or repeatedly
Slurring or prominent slowing
Marked relaxation (slack jaw)
Glazed and marked ptosis (half the eye or more)
3

Responds only after mild prodding or shaking
Few recognizable words
—
—
2

Does not respond to mild prodding or shaking
—
—
—
1 (deep sleep)

Patients were randomized to receive a loading infusion of either dexmedetomidine 1 mcg/kg, dexmedetomidine 0.5 mcg/kg, or placebo (normal saline) given over 10 minutes and followed by a maintenance infusion started at 0.6 mcg/kg/hr. The maintenance infusion of study drug could be titrated from 0.2 mcg/kg/hr to 1 mcg/kg/hr to achieve the targeted sedation score (Observer’s Assessment of Alertness/Sedation Scale ≤ 4). Patients were allowed to receive rescue midazolam as needed to achieve and/or maintain an Observer’s Assessment of Alertness/Sedation Scale ≤ 4. After achieving the desired level of sedation, a local or regional anesthetic block was performed. Demographic characteristics were similar between the dexmedetomidine and comparator groups. Efficacy results showed that dexmedetomidine was more effective than the comparator group when used to sedate non- intubated patients requiring monitored anesthesia care during surgical and other procedures. (see Table 13)

In Study 2, the sedative properties of dexmedetomidine were evaluated by comparing the percent of patients requiring rescue midazolam to achieve or maintain a specified level of sedation using the Ramsay Sedation Scale score ≥ 2 (see Table 9).

Patients were randomized to receive a loading infusion of dexmedetomidine 1 mcg/kg or placebo (normal saline) given over 10 minutes and followed by a fixed maintenance infusion of 0.7 mcg/kg/hr. After achieving the desired level of sedation, topicalization of the airway occurred. Patients were allowed to receive rescue midazolam as needed to achieve and/or maintain a Ramsay Sedation Scale ≥ 2. Demographic characteristics were similar between the dexmedetomidine and comparator groups. For efficacy results see Table 13.
Table 13: Key Efficacy Results of Procedural Sedation Studies

Study

Loading Infusion Treatment Arm

Number of Patients Enrolled Based on ITT population defined as all randomized and treated patients.

% Not Requiring Midazolam Rescue

Confidence Normal approximation to the binomial with continuity correction. Interval on the Difference vs. Placebo

Mean (SD) Total Dose (mg) of Rescue Midazolam Required

Confidence Intervals of the Mean Rescue Dose

Study 1

Dexmedetomidine 0.5 mcg/kg

134
40
37 (27, 48)
1.4 (1.7)
-2.7 (-3.4, -2.0)

Dexmedetomidine 1 mcg/kg

129
54
51 (40, 62)
0.9 (1.5)
-3.1 (-3.8, -2.5)

placebo
63
3
—
4.1 (3.0)
—

Study 2

Dexmedetomidine 1 mcg/kg

55
53
39 (20, 57)
1.1 (1.5)
-1.8 (-2.7, -0.9)

placebo
50
14
—
2.9 (3.0)
—

16 How Supplied/storage And Handling


Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature.]

Do not use if product is discolored or if precipitate matter is present.

Dexmedetomidine injection, USP 200 mcg/2 mL (100 mcg/mL) is clear and colorless. The strength is based on the dexmedetomidine base. Discard unused portion
NDC No. Container Size

16729-239-30
Vial
2 mL Single Dose Vial

16729-239-93
Vial
25 Units of 2 mL Single Dose Vial in a Carton

17 Patient Counseling Information


Dexmedetomidine injection is indicated for short-term intravenous sedation. Dosage must be individualized and titrated to the desired clinical effect. Blood pressure, heart rate and oxygen levels will be monitored both continuously during the infusion of dexmedetomidine injection and as clinically appropriate after discontinuation.
  • When dexmedetomidine injection is infused for more than 6 hours, patients should be informed to report nervousness, agitation, and headaches that may occur for up to 48 hours.
  • Additionally, patients should be informed to report symptoms that may occur within 48 hours after the administration of dexmedetomidine injection such as: weakness, confusion, excessive sweating, weight loss, abdominal pain, salt cravings, diarrhea, constipation, dizziness or light-headedness.
  • Advise breastfeeding mothers who were exposed to dexmedetomidine injection to monitor breastfed neonates for irritability [see Use in Specific Populations (8.2)].

Manufactured For:

Accord Healthcare, Inc.,

1009, Slater Road,

Suite 210-B,

Durham, NC 27703,

USA.

Manufactured By:

Intas Pharmaceuticals Limited,

Ahmedabad 380 054, India.

10 1651 4 6020022

Issued October, 2022

INP163

Package Label.principal Display Panel


PRINCIPAL DISPLAY PANEL

Dexmedetomidine HCL Injection

NDC 16729- 239-30

200 mcg (Dexmedetomidine)/2 mL [100 mcg (Dexmedetomidine)/mL] Label

Rx only

For IV use MUST BE DILUTED

Dexmedetomidine HCL Injection

NDC 16729- 239-93

200 mcg (Dexmedetomidine)/2 mL [100 mcg (Dexmedetomidine)/mL] Carton

Rx only

For IV use MUST BE DILUTED

Dexmedetomidine HCL Injection

NDC 16729- 239-30

200 mcg (Dexmedetomidine)/2 mL [100 mcg (Dexmedetomidine)/mL] Label

Rx only

For IV use MUST BE DILUTED

Dexmedetomidine HCL Injection

NDC 16729- 239-93

200 mcg (Dexmedetomidine)/2 mL [100 mcg (Dexmedetomidine)/mL] Carton

Rx only

For IV use MUST BE DILUTED

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site